182 related articles for article (PubMed ID: 28581032)
21. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction.
Omar H; Hägglund H; Gustafsson-Jernberg A; LeBlanc K; Mattsson J; Remberger M; Ringdén O; Sparrelid E; Sundin M; Winiarski J; Yun Z; Ljungman P
Transpl Infect Dis; 2009 Oct; 11(5):393-9. PubMed ID: 19497070
[TBL] [Abstract][Full Text] [Related]
22. Pre-emptive therapy with rituximab for prevention of Epstein-Barr virus-associated lymphoproliferative disease after hematopoietic stem cell transplantation.
Gruhn B; Meerbach A; Häfer R; Zell R; Wutzler P; Zintl F
Bone Marrow Transplant; 2003 Jun; 31(11):1023-5. PubMed ID: 12774054
[TBL] [Abstract][Full Text] [Related]
23. Prognostic factors and outcome of Epstein-Barr virus DNAemia in high-risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab.
Patriarca F; Medeot M; Isola M; Battista ML; Sperotto A; Pipan C; Toffoletti E; Dozzo M; Michelutti A; Gregoraci G; Geromin A; Cerno M; Savignano C; Rinaldi C; Barbone F; Fanin R
Transpl Infect Dis; 2013 Jun; 15(3):259-67. PubMed ID: 23405972
[TBL] [Abstract][Full Text] [Related]
24. Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction.
Kinch A; Oberg G; Arvidson J; Falk KI; Linde A; Pauksens K
Scand J Infect Dis; 2007; 39(3):235-44. PubMed ID: 17366054
[TBL] [Abstract][Full Text] [Related]
25. [Prevalence of EBV infection in patients with allogeneic hematopoietic stem cell transplantation].
Han TT; Xu LP; Liu DH; Liu KY; Zhang XH; Chen H; Chen YH; Han W; Wang FR; Wang Y; Wang JZ; Huang XJ
Zhonghua Xue Ye Xue Za Zhi; 2013 Aug; 34(8):651-4. PubMed ID: 23978013
[TBL] [Abstract][Full Text] [Related]
26. Impact of Epstein Barr virus-related complications after high-risk allo-SCT in the era of pre-emptive rituximab.
García-Cadenas I; Castillo N; Martino R; Barba P; Esquirol A; Novelli S; Orti G; Garrido A; Saavedra S; Moreno C; Granell M; Briones J; Brunet S; Navarro F; Ruiz I; Rabella N; Valcárcel D; Sierra J
Bone Marrow Transplant; 2015 Apr; 50(4):579-84. PubMed ID: 25581404
[TBL] [Abstract][Full Text] [Related]
27. [The efficacy and safety of donor lymphocyte infusion to treat Epstein-Barr virus associated lymphoproliferative diseases after allogeneic hematopoietic stem cell transplantation].
Xu LP; Liu DH; Liu KY; Chen H; Han W; Wang Y; Wang J; Shi HX; Huang XJ
Zhonghua Nei Ke Za Zhi; 2010 Nov; 49(11):955-8. PubMed ID: 21211211
[TBL] [Abstract][Full Text] [Related]
28. [Quantitative monitoring of mononucleated cell Epstein-Barr virus (EBV)-DNA for predicting EBV associated lymphoproliferative disorders after stem cell transplantation.].
Wang LH; Ren HY; Sun YH; Qiu ZX; Cen XN; Ou JP; Xu WL; Wang MJ; Wang WS; Li Y; Dong YJ; Yin Y; Liang ZY
Zhonghua Xue Ye Xue Za Zhi; 2010 Feb; 31(2):73-6. PubMed ID: 20302791
[TBL] [Abstract][Full Text] [Related]
29. Reduced PTLD-related mortality in patients experiencing EBV infection following allo-SCT after the introduction of a protocol incorporating pre-emptive rituximab.
van der Velden WJ; Mori T; Stevens WB; de Haan AF; Stelma FF; Blijlevens NM; Donnelly JP
Bone Marrow Transplant; 2013 Nov; 48(11):1465-71. PubMed ID: 23749107
[TBL] [Abstract][Full Text] [Related]
30. Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation.
Comoli P; Basso S; Zecca M; Pagliara D; Baldanti F; Bernardo ME; Barberi W; Moretta A; Labirio M; Paulli M; Furione M; Maccario R; Locatelli F
Am J Transplant; 2007 Jun; 7(6):1648-55. PubMed ID: 17511690
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of use of Epstein-Barr viral load in patients after allogeneic stem cell transplantation to diagnose and monitor posttransplant lymphoproliferative disease.
Gärtner BC; Schäfer H; Marggraff K; Eisele G; Schäfer M; Dilloo D; Roemer K; Laws HJ; Sester M; Sester U; Einsele H; Mueller-Lantzsch N
J Clin Microbiol; 2002 Feb; 40(2):351-8. PubMed ID: 11825941
[TBL] [Abstract][Full Text] [Related]
32. Epstein-Barr virus (EBV) reactivation in allogeneic stem-cell transplantation: relationship between viral load, EBV-specific T-cell reconstitution and rituximab therapy.
Clave E; Agbalika F; Bajzik V; Peffault de Latour R; Trillard M; Rabian C; Scieux C; Devergie A; Socié G; Ribaud P; Adès L; Ferry C; Gluckman E; Charron D; Esperou H; Toubert A; Moins-Teisserenc H
Transplantation; 2004 Jan; 77(1):76-84. PubMed ID: 14724439
[TBL] [Abstract][Full Text] [Related]
33. Lymphoproliferative disease after allogeneic stem cell transplantation--pre-emptive diagnosis by quantification of Epstein-Barr virus DNA in serum.
Aalto SM; Juvonen E; Tarkkanen J; Volin L; Ruutu T; Mattila PS; Piiparinen H; Knuutila S; Hedman K
J Clin Virol; 2003 Dec; 28(3):275-83. PubMed ID: 14522066
[TBL] [Abstract][Full Text] [Related]
34. Successful treatment of Rituximab-resistant Epstein-Barr virus-associated post-transplant lymphoproliferative disorder using R-CHOP.
Kuriyama T; Kawano N; Yamashita K; Ueda A
J Clin Exp Hematop; 2014; 54(2):149-53. PubMed ID: 25318948
[TBL] [Abstract][Full Text] [Related]
35. Incidence and risk factors of EBV reactivation after unrelated cord blood transplantation: a Eurocord and Société Française de Greffe de Moelle-Therapie Cellulaire collaborative study.
Dumas PY; Ruggeri A; Robin M; Crotta A; Abraham J; Forcade E; Bay JO; Michallet M; Bertrand Y; Socié G; Ionescu I; Gluckman E; Milpied N; Rocha V
Bone Marrow Transplant; 2013 Feb; 48(2):253-6. PubMed ID: 22773124
[TBL] [Abstract][Full Text] [Related]
36. [The efficacy and safety of rituximab in treatment of Epstein-Barr virus disease post allogeneic hematopoietic stem-cell transplantation].
Xu LP; Liu DH; Liu KY; Zhang CL; Wang FR; Wang JZ; Wang Y; Chen H; Zhang YY; Yan CH; Han W; Chen YH; Zhao T; Zhang XH; Huang XJ
Zhonghua Nei Ke Za Zhi; 2012 Dec; 51(12):966-70. PubMed ID: 23327959
[TBL] [Abstract][Full Text] [Related]
37. Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases.
Nash RA; Dansey R; Storek J; Georges GE; Bowen JD; Holmberg LA; Kraft GH; Mayes MD; McDonagh KT; Chen CS; Dipersio J; Lemaistre CF; Pavletic S; Sullivan KM; Sunderhaus J; Furst DE; McSweeney PA
Biol Blood Marrow Transplant; 2003 Sep; 9(9):583-91. PubMed ID: 14506660
[TBL] [Abstract][Full Text] [Related]
38. Features of Epstein-Barr virus reactivation after allogeneic hematopoietic cell transplantation in Korean children living in an area of high seroprevalence against Epstein-Barr virus.
Han SB; Bae EY; Lee JW; Jang PS; Lee DG; Chung NG; Jeong DC; Cho B; Lee SJ; Kang JH; Kim HK
Int J Hematol; 2014 Aug; 100(2):188-99. PubMed ID: 24981711
[TBL] [Abstract][Full Text] [Related]
39. The impact of monitoring Epstein-Barr virus PCR in paediatric bone marrow transplant patients: can it successfully predict outcome and guide intervention?
Greenfield HM; Gharib MI; Turner AJ; Guiver M; Carr T; Will AM; Wynn RF
Pediatr Blood Cancer; 2006 Aug; 47(2):200-5. PubMed ID: 16206207
[TBL] [Abstract][Full Text] [Related]
40. EBV-associated post-transplant lymphoproliferative disorder following in vivo T-cell-depleted allogeneic transplantation: clinical features, viral load correlates and prognostic factors in the rituximab era.
Fox CP; Burns D; Parker AN; Peggs KS; Harvey CM; Natarajan S; Marks DI; Jackson B; Chakupurakal G; Dennis M; Lim Z; Cook G; Carpenter B; Pettitt AR; Mathew S; Connelly-Smith L; Yin JA; Viskaduraki M; Chakraverty R; Orchard K; Shaw BE; Byrne JL; Brookes C; Craddock CF; Chaganti S
Bone Marrow Transplant; 2014 Feb; 49(2):280-6. PubMed ID: 24212561
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
